Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2008

01-08-2008 | Preclinical Study

Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables

Authors: Woo Chul Noh, Yang Hee Kim, Min Suk Kim, Jae Soo Koh, Hyun-Ah Kim, Nan Mo Moon, Nam-Sun Paik

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Login to get access

Abstract

Aims

Rapamycin and its analogues are currently being tested in clinical trials as novel–targeted anticancer agents. Pre-clinical studies that used breast cancer cell lines have suggested that p-Akt or p-S6K1 expressing tumors, as well as PTEN negative tumors, were sensitive to rapamycin. The aims of this study were to determine the proportion of breast cancer that could be candidates for rapamycin treatment and to elucidate the clinicopathologic characteristics and prognosis of potentially rapamycin-sensitive tumors.

Methods

We evaluated the expressions of PTEN, p-Akt and p-S6K1 by performing immunohistochemistry in 122 breast cancer tissues. We analyzed the association of the expression of these proteins with the cliniopathologic variables and the disease-free survival.

Results

PTEN negative tumors, p-Akt expressing tumors and p-S6K1 expressing tumors constituted 4.1% (5/122), 41.0% (50/122), and 36.1% (44/122) of the total tumors, respectively. The proportion of tumors that met the criteria of rapamycin sensitivity was 54.9% (67/122). We could not find any significant correlation between the expression of these proteins and the other prognostic factors. However, the prognosis of tumors with a p-S6K1 expression was significantly worse than that of the p-S6K1 negative tumors.

Conclusion

Based on the status of the PTEN, p-Akt and p-S6K1 expressions as predictors of rapamycin sensitivity, this study suggested that over 50% of breast cancer patients could be potential candidates for rapamycin treatment. In addition, the p-S6K1 expression may constitute an independent prognostic factor for disease-free survival.
Literature
1.
Vignot S, Faivere S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525–537PubMedCrossRef
2.
Rowinsky EK (2004) Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16:564–575PubMedCrossRef
3.
Noh WC, Paik NS (2003) Translational regulation: a novel target for breast cancer therapy. J Korean Breast Cancer Soc 6:8–14
4.
Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-Cancer Drug 16:797–803CrossRef
5.
Carraway H, Hidalgo M (2004) New target for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6:219–224PubMedCrossRef
6.
Garber K (2001) Rapamycin’s resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst 93:1517–1519PubMedCrossRef
7.
Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336–2347PubMedCrossRef
8.
O’Donnell M, Faivre I, Judson C et al (2003) A phase I study of oral mTOR inhibitor RAD 001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic and pharmacodynamic endpoints in patients with solid tumors. Proc Am Soc Clin Oncol 22:200
9.
Chan S, Scheulen ME, Johston S et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314–5322PubMedCrossRef
10.
DeGraffenried LA, Friedrichs WE, Russel DH et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10:8059–8067PubMedCrossRef
11.
Osborne CK, Shou J, Massarweh S et al (2005) Crosstalk between estrogen receptor and growth factor receptor pathway as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s–870sPubMed
12.
Chow LWC, Sun Y, Jassem J et al (2006) Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Paper presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2006
13.
Noh WC, Mondesire WH, Peng J et al (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013–1023PubMedCrossRef
14.
Yu K, Toral-Barza L, Discafani C et al (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249–258PubMedCrossRef
15.
Allred D, Bustamante M, Daniel C et al (1990) Immunohistochemical analysis of estrogen receptors in human breast carcinomas. Arch Surg 125:107–116PubMed
16.
Xu G, Zhang W, Bertram P, Zheng X et al (2004) Pharmacogenomic profiling of PI3K/PTEN-Akt-mTOR pathway in common breast tumors. Int J Oncol 24:893–900PubMed
17.
Mills GB, Lu Y, Fang X et al (2001) The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 28:125–141PubMedCrossRef
18.
Nelen MR, van Staveren WC, Peeters E et al (1997) Germline mutation in the PTEN/MMAC-1 gene in patients with Cowden disease. Human Mol Genet 6:1384–1387
19.
Rhei E, Kang L, Bogomolniy F et al (1997) Mutation analysis of putative tumor suppressor gene PTEN/MMAC-1 in primary breast carcinomas. Cancer Res 57:3657–3659PubMed
20.
Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in brain, breast, and prostate cancer. Science 275:1943–1947PubMedCrossRef
21.
Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 14:381–395PubMedCrossRef
22.
Meric F, Hung MC, Hortobagyi GN et al (2002) HER2/neu in management of invasive breast cancer. J Am Coll Surg 194:488–501PubMedCrossRef
23.
Zhou X, Tan M, Hawthorne VS et al (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by erbB-2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 15:6779–6788CrossRef
24.
Tokunaga E, Kataoka A, Kimura Y et al (2006) The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 42:629–635PubMedCrossRef
25.
Schmitz KJ, Otterbach F, Callies R et al (2004) Prognostic relevance of activated Akt kinase in node negative breast cancer: a clinicopathologic study of 99 cases. Modern Pathol 17:15–21CrossRef
26.
Barlund M, Forozan F, Kononen J et al (2000) Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 92:1252–1259PubMedCrossRef
27.
Hage JA, Broek LJCM, Legrand C et al (2004) Overexpression of P70 S6 kinase protein is associated with risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer 90:1543–1550PubMedCrossRef
28.
Peralba JM, DeGraffenried LA, Friedrichs WE et al (2003) Phamacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887–2892PubMed
Metadata
Title
Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables
Authors
Woo Chul Noh
Yang Hee Kim
Min Suk Kim
Jae Soo Koh
Hyun-Ah Kim
Nan Mo Moon
Nam-Sun Paik
Publication date
01-08-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9746-x

Other articles of this Issue 3/2008

Breast Cancer Research and Treatment 3/2008 Go to the issue

Preclinical Study

The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome

Preclinical Study

Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases

Letter to the editor

Post-diagnosis statin use and breast recurrence sites in early stage breast cancer survivors

Preclinical Study

Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria

Preclinical Study

Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers

Review

Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits